Evidence Of Genetic Testing In A Large, Real-world DCM Cohort And Association With Heart Failure Risk
Kanchan Bhasin,Mauro Longoni,Andrew Ward,McKenna Nisson,Brent White,Donghyun Lee,Sucheta Bhatt,Fatima Rodriguez,Rajesh Dash
DOI: https://doi.org/10.1016/j.cardfail.2023.10.029
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Dilated Cardiomyopathy (DCM) is a significant cause of congestive heart failure (HF). Understanding the etiology of the left ventricular dysfunction leading to DCM may inform clinical care and prevent subsequent progression to HF. Current clinical guidelines recommend genetic testing for all patients with a diagnosis of DCM or with a family history of DCM; however, the association between guideline-directed genetic testing and progression to clinical HF in DCM patients has yet to be determined. Objective To determine the association of early guideline-directed genetic testing and new-onset HF in patients with DCM. Methods A retrospective analysis of linked Veradigm EHR and claims data (35 million US patients) was conducted to identify patients newly diagnosed with DCM with no prior HF between 01/01/2018-12/31/2021. Bivariate analyses examined the association between new-onset HF, defined as the first diagnosis of HF via ICD-10 codes after a wash-in period of 1 year with no diagnosis of HF, and over 200 patient features, including guideline-directed interventions (e.g. pacemaker placement). A Cox proportional hazards regression model was used to examine the association between genetic testing (via CPT, ICD-10, and text) within the 6 months prior to initial diagnosis of DCM and the rate of new-onset HF, controlling for patient features. Results There were 38,362 patients with a new diagnosis of DCM and no prior HF; of these, only 408 patients (1.1%) received guideline-directed genetic testing in the 6 months before DCM diagnosis. There was an inverse association between genetic testing and new-onset HF (hazard ratio 0.81, 95% confidence interval 0.67-0.99), after controlling for patient demographics, medications, comorbidities, laboratory results, and vital signs (Figure 1). Pacemaker placement was associated with comparably lower HF rates (hazard ratio 0.86, 95% confidence interval 0.77-0.97). There was a consequent impact on HF-free survival curves in the genetic testing cohort (inset, Figure 1). Conclusion Genetic testing prior to a clinical diagnosis of DCM is statistically associated with a lower rate of HF, after controlling for other factors. Future work will focus on whether establishing a genetic etiology impacts the course of clinical care and, consequently, the progression to HF.
cardiac & cardiovascular systems